ArticleJournal of pharmaceutical health care and sciences2026
The impact of pharmacist-led medication therapy management on the efficacy of cancer pain control: a pre-post interventional study.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCancer pain remains a prevalent and debilitating symptom among patients with advanced malignancies, significantly compromising quality of life. While clinical guidelines for pain management exist, real-world challenges such as polypharmacy, poor adherence, and drug-related problems (DRPs) hinder effective treatment. Pharmacist-led Medication Therapy Management (MTM) offers a structured approach to address these challenges, but its role in cancer pain management remains underexplored.
aimThis study aimed to evaluate the effect of pharmacist-led MTM on cancer pain management.
methodsA pre-post interventional study was conducted using the MTM services implemented in January 2023.
resultsA total of 246 patients were included in the pre-MTM group (n = 100) and MTM (n = 146) groups. Pharmacist-led MTM was associated with better cancer pain score at 30-day follow-up (3.85 ± 1.07 VS 4.85 ± 1.47, P < 0.001) and greater reduction in pain scores (1.92 ± 0.84 VS 2.81 ± 1.21, P < 0.001) compared to the pre-MTM group. In Additional, the MTM effectively identified and resolved the DRPs, achieving a resolution rate of 73.81%. A lower incidence of adverse drug reactions, including constipation, nausea, and vomiting, was observed in the MTM group (P < 0.05). Furthermore, pharmacist-led MTM was associated with a higher proportion of patients with high medication adherence, with 67.81% in the MTM group compared with 45% in the pre-MTM group (P < 0.001). Pharmacist-led MTM was associated with higher patient satisfaction with treatment (4.71 ± 1.14 vs. 3.04 ± 2.07, P < 0.001) and follow-up (3.92 ± 1.76 vs. 3.46 ± 1.70, P = 0.02) compared with the pre-MTM group.
conclusionPharmacist-led MTM plays a crucial role in optimizing cancer pain management by reducing DRPs, improving adherence, minimizing adverse drug reactions, and enhancing patient satisfaction. It is an essential component of comprehensive, individualized care that ultimately improves the clinical outcomes and quality of life of patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.